Merck & Company (MRK) 60.76 $MRK
U.S. Northeast Remains Life-Science Darling, Attracting $8 Billion in Capital Investment, an Industrial Info News Alert
Marketwire - 11 mins ago
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Like any long-term union, the one shared between the U.S. Northeast region, which comprises Delaware, New Jersey, New York and Pennsylvania, and the Life Science Industry is a classic example of a love/hate relationship. The Northeast region has been pummeled over the past few years with scores of pharmaceutical plants closing and lucrative jobs lost. On the other hand, the region remains a favorite for capital investment from both the private and public sectors for new and upgraded life-science manufacturing plants and research centers. Currently, there are 147 active reported projects translating to a hefty $7.8 billion in total investment value.
Global Migraine Drug Forecast and Market Analysis to 2023 - A Potential $3.7 Billion Market
M2 - 1 hr 34 mins ago
Research and Markets (http://www.researchandmarkets.com/research/5qmmg2/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023" report to their offering. The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile. Key Findings - The main driver of the expansion of the migraine market will be the continuous use of Botox for chronic migraine. The introduction of reformulations of mature products as well as new classes of therapies will further increase the market size. - The biggest barrier for the introduction of new therapies will be patent expirations of the majority of the drugs marketed for migraine, which have resulted in an increase of generics, and which may negatively impact revenue from branded drugs that are expected to launch in the forecast period. - The concerns of reducing healthcare costs as part of government austerity measures, particularly in Europe, which will impede market growth. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - GlaxoSmithKline - AstraZeneca - Merck - Vernalis - Almirall - Pfizer - Zogenix - NuPathe - Allergan - RedHill Biopharma - OptiNose - CoLucid Pharmaceuticals - SUDA - Revance Therapeutics - NeurAxon For more information visit http://www.researchandmarkets.com/research/5q...harmapoint
Ligand Inks 2nd Captisol Deal with CURx Pharmaceuticals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 4:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a licensing deal with CURx Pharmaceuticals, under which the former's Captisol-enabled lamotrigine program will be developed and commercialized.
Pipeline Analysis of Hospital Acquired Pneumonia Drugs 2014-2020: Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix
M2 - Wed Sep 10, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r49n8b/pipeline_analysis) has announced the addition of the "Pipeline Analysis of Hospital Acquired Pneumonia Drugs - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of hospital acquired pneumonia are common in immunocompromised patients, post surgical infections, enteral feeding, elderly and infant patients. As hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator associated pneumonia. Major causative pathogens include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne. Currently there are four drugs authorized for treatment of hospital acquired pneumonia; these include Zosyn (piperacillin/tazobactam), Zyvox (linezolid), Tygacil (tigecycline), and Vibativ (telavancin). Consistent research and development is being conducted in view of introducing more effective treatment options. There are five investigational drugs and one vaccine in stage III clinical trials, while ten other candidates in early stage, which mainly include biological drugs. Tedizolid phosphate and ceftolozane/tazobactam by Cubist Pharmaceutical, ceftazidime/avibactam by AstraZeneca PLC, amikacin inhale by Bayer Healthcare, plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline are the phase III candidates. Considering the antibacterial efficiency, and current market competition, tedizolid phosphate is expected to be the most preferred drug for treatment of nosocomial pneumonia. Amikacin inhale, an aerosolized drug is intended for sale as a drug device combination. Majority of the drugs in the late stages are biological drugs. Aridis Pharmaceutical holds four investigational drugs against various causative agents of hospital acquired pneumonia, each being monoclonal antibody therapy. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market overview Chapter 4 Hospital Acquired Pneumonia, Pipeline Analysis Chapter 5 Global Pipeline Review of Hospital Acquired Pneumonia Drugs Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Valneva SE - Achaogen, Inc. - Aridis Pharmaceuticals - AstraZeneca plc - Cubist Pharmaceuticals, Inc. - GlaxoSmithKline, Inc. - Meiji Seika Pharma Co. Ltd. - Merck & Co. Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/r4...e_analysis
Dow Component Merck (MRK) To Go Ex-dividend Tomorrow
at The Street - Wed Sep 10, 10:00AM CDT
Thursday, September 11, 2014 is the ex-dividend date for Dow component (NYSE:MRK).
Global Diclofenac Market Report 2014-2019
M2 - Wed Sep 10, 9:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tmxmbx/global_diclofenac) has announced the addition of the "Global Diclofenac Industry Report 2014" report to their offering. The report provides an basic overview of the industry including definitions, classifications, applications and industry chain structure. The diclofenac market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Diclofenac industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on twenty-six industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The diclofenac industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Diclofenac Industry Overview - Global Diclofenac Market Status Analysis - Major Regions Diclofenac Market Status Analysis - Major Countries Diclofenac Market Status and Analysis - Major Companies Diclofenac Market Status and Analysis - Diclofenac Industry Chain and Marketing Channels Analysis - Diclofenac Industry Development Trend - Diclofenac New Project Investment Feasibility Analysis - Global Diclofenac Industry Research Conclusions Companies Mentioned - A. S. Joshi And Company - Asa Biotech - Ausun - Anyang Jiuzhou Pharmaceutical Co., Ltd. - Bayer - Cpu-Pharma - Dezhou Deyao Pharmaceutical Co.,Ltd - Hainan Poly Pharm - Istituto Biochimico Italiano Spa - Iroko - Kahan Pharmaceuticals - Merck Sharp & Dohme Corp. - Metrix Healthcare Private Limited - Novartis - Nipa Pharmaceuticals Limited - Pku Healthcare Corp.,Ltd - Pfizer - Raazee Therapeutics (Pvt) Ltd. - Simcere - Sunij - Suzhou Homesun Pharmaceutical Co.,Ltd - Sri Pharmacare - Warrant Pharmaceutical - Yung Zip Chemical Co. Limited - Yangtze River Pharmaceutical Group - Zhejiang Jinhua Conba Bio-Pharm Co.Ltd For more information visit http://www.researchandmarkets.com/research/tm...diclofenac About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Merck & Co.'s Keytruda is Approved in the United States for the Treatment of Advanced and Unresectable Malignant Melanoma
PR Newswire - Wed Sep 10, 9:00AM CDT
The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma. Decision Resources Group will track the launch of Keytruda throughout its first year on the market through our syndicated LaunchTrends report series.
OTC Drug Market in India 2014
M2 - Wed Sep 10, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2nxxm7/otc_drug_market) has announced the addition of the "OTC Drug Market in India 2014 " report to their offering. This latest market research report titled OTC Drug Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing self-medicated patient population, growing confidence in OTC drugs, and change of prescription drugs to OTC drugs are the key drivers of this market. The various segments of OTC drugs such as Vitamins & Minerals, Gastrointestinal, and Cough Cold & Allergy etc. are the major reasons for the popularity of the OTC drug market. Growing number of self-treatment patient base and their confidence in the OTC drugs is helping the Indian market to grow. Prescription drugs, after becoming OTC, present a huge opportunity for growth. OTC drugs increase the availability of different types of drugs intended for self-medication among patients, which helps in the growth of the market. The increasing disposable income of people is also helping to boost the market size. Some challenges faced by the industry are the internal competition between large pharmaceutical companies. Another challenge is the penetration of OTC drugs in rural areas which is very low. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well. Key Topics Covered: - Executive Summary - Macroeconomic Indicators - Introduction - Market Overview - Value Chain - Drivers & Challenges - Government Initiatives - Regulations - Competitive Landscape - Recent Developments - Strategic Recommendation - Appendix Companies Mentioned Public Companies - Amrutanjan Healthcare Ltd. - Cipla Ltd. - Dr. Reddy's Laboratories Ltd. - GlaxoSmithKline Pharmaceuticals Ltd. - Lupin Ltd. - Novartis India Ltd. - Pfizer Ltd. - P&G - Ranbaxy Laboratories Ltd. - Merck Ltd Sun Pharmaceutical Industries Ltd.. For more information visit http://www.researchandmarkets.com/research/2n...rug_market
Broccolini and Magil Laurentian Announce the Acquisition of the Former Merck Canada Complex in Kirkland, Quebec
PR Newswire Europe - Tue Sep 09, 5:10PM CDT
KIRKLAND, Quebec, September 9, 2014 /PRNewswire/ --
TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:00PM CDT
TESARO, Inc. (TSRO) submitted a new drug application for its pipeline candidate, oral rolapitant, to the FDA.
Broccolini and Magil Laurentian announce the acquisition of the former Merck Canada complex in Kirkland, Quebec
PR Newswire - Tue Sep 09, 2:08PM CDT
Broccolini Limited Partnership No. 2 and Magil Laurentian Realty Investments announced today that they have closed on the acquisition of the former Merck Canada complex along the TransCanada Highway in Kirkland, Quebec. Broccolini and Magil Laurentian have joined forces to develop this world-class 50-acre business and mixed-use campus which was renamed "Quartier Évolution". The partnership between Broccolini and Magil Laurentian brings together a qualified team of professionals in construction, real estate development and property management, in order to fully meet the needs of future tenants.
Watch for Shares of Merck (MRK) to Approach Support at $60.57
Comtex SmarTrend(R) - Tue Sep 09, 12:26PM CDT
Merck (NYSE:MRK) has opened bearishly below the pivot of $61.07 today and has reached the first level of support at $60.81. Analysts will be watching for a cross of the next downside pivot targets of $60.57 and $60.07.
Cardiovascular Pharmaceuticals Market in India 2014
M2 - Tue Sep 09, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rgkkvk/cardiovascular) has announced the addition of the "Cardiovascular Pharmaceuticals Market in India 2014" report to their offering. This market research report titled Cardiovascular Pharmaceutical Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing patient population, patent expiry of blockbuster drugs, and introduction of newer and better drugs are the key drivers of this market. Cardiovascular pharmaceuticals is one of the leading therapeutic segments of the overall pharma industry and cardiovascular diseases (CVDs) are the top causes of deaths worldwide Growing incidences of cardiovascular diseases is helping the Indian market to grow and large pharmaceutical companies are trying to launch new patented blockbuster drugs to tackle the situation. Patented blockbuster drugs, after becoming generic, present a huge opportunity for growth. Generic drugs increase the affordability among patients, which helps in the growth of the market. The increasing disposable income of people are also helping to boost the market size. Some challenges faced by the industry are the internal competition between large pharmaceutical companies and competition from complementary and alternative medicines. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well Key Topics Covered: - Executive Summary - Macroeconomic Indicators - Introduction - Market Overview - Value Chain - Drivers & Challenges - Government Initiatives - Competitive Landscape - Recent Developments - Strategic Recommendation - Appendix Companies Mentioned Public Companies: - AstraZeneca Pharma India Ltd. - Sanofi India Ltd. - Cipla Ltd. - Dr. Reddy's Laboratories Ltd. - GlaxoSmithKline Pharmaceuticals Ltd. - Lupin Ltd. - Merck Ltd. - Novartis India Ltd. - Pfizer Ltd. - Ranbaxy Laboratories Ltd. - Sun Pharmaceutical Industries Ltd. - Torrent Pharmaceutical Ltd. Private Companies: - Bristol-Myers Squibb India Pvt. Ltd. - Cadila Pharmaceuticals Ltd. - Intas Pharmaceuticals Ltd. - USV Ltd. For more information visit http://www.researchandmarkets.com/research/rg...iovascular
Four New Partner Organizations Join Optum Labs Research Collaborative
Business Wire - Tue Sep 09, 7:01AM CDT
Optum Labs, the collaborative research and innovation center co-founded by Optum and Mayo Clinic, announced the addition of four new partners committed to improving the quality and value of patient care.
Merck kicks off its second year fight against diabetes by adopting e-learning solutions to build healthcare capacity in Africa
M2 - Tue Sep 09, 6:52AM CDT
- Merck is reaching to health professionals in rural areas by providing SMS and e-learning platform for diabetes
Global Infectious Disease Treatment Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, GSK, J&J Merck & Pfizer
M2 - Tue Sep 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5tdjb4/global_infectious) has announced the addition of the "Global Infectious Disease Treatment Market 2014-2018" report to their offering. The analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 3.43% over the period 2013-2018. Infectious diseases can be caused by various pathogenic microorganisms such as bacteria, fungi, parasites, or viruses. These diseases can be transmitted from one individual to another through either direct contact or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on the target organism, anti-infective drugs can be categorized into antibacterial, antiviral, antifungal, and antiparasitic. One of the emerging trends in this market is the emergence of Interferon-free regimens. Various all-oral, IFN-free regimens are under development and are expected to attain higher sustained virologic response and cause fewer side effects than the currently approved therapies. According to the report, the launch of Direct-acting Antivirals is one of the major drivers for the Global Infectious Disease Treatment market. DAAs are administered in combination with other antiviral drugs such as ribavirin and PEG-IFN and increase the efficacy of treatment and decrease the duration of therapy and this leads to increased preference for this treatment among patients. Further, the report states that a generic erosion of marketed drugs is one of the major challenges faced by the market. A loss of patent protection and market exclusivity generally triggers the entry of low-cost alternatives for drugs, which, in turn, decreases the sales of innovator-approved drugs. To calculate the market size, the report considers the revenue generated through the sales of various drugs administered to treat various infectious diseases caused by bacteria, virus, fungi, and parasites, which include: - Antibacterial drugs (beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, sulfonamides, tetracyclines, and other antibacterials) - Antiviral drugs (HIV, hepatitis C, hepatitis B, and other antivirals) - Antifungal drugs (azoles, pyrimidines, echinodians, polyenes, allylamines, and other antifungal drugs) - Antiparasitic drugs Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck - Pfizer For more information visit http://www.researchandmarkets.com/research/5t...infectious
Acucela Appoints Biotechnology Industry Veteran and Former Pharmaceutical Executive, Brian O'Callaghan, as Its New President and Chief Operating Officer and Interim CFO; Ryo Kubota, MD, PhD, to Remain in His Role as Chairman and CEO
Business Wire - Mon Sep 08, 7:15PM CDT
Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that after a long and thoughtful strategic planning process to recruit a new President and Chief Operating Officer (COO), Acucela has appointed Brian O'Callaghan, who currently sits on Acucela's Board of Directors, to the newly created position, effective immediately. Ryo Kubota, MD, PhD, who is also Acucela's Founder, will remain as Acucela's Chairman of the Board (Chairman) and Chief Executive Officer (CEO). In a separate development, Acucela's Chief Financial Officer (CFO), David Lowrance, will be leaving the Company for family reasons. As a result of Mr. Lowrance's departure, Mr. O'Callaghan will also assume the role of Interim CFO. An active search is underway to appoint a new CFO. Mr. O'Callaghan brings to Acucela over 25 years of leadership experience in the biotechnology and pharmaceutical industries, including senior positions at Bayer, Merck, Novartis, NPS Pharmaceuticals, Pfizer, and Sangart. He will report directly into Dr. Kubota.
Merck to Participate at the Morgan Stanley Global Healthcare Conference
Business Wire - Mon Sep 08, 4:00PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer; Adam H. Schechter, executive vice president and president, Global Human Health; and Dr. Roy Baynes, senior vice president, Clinical Development, Merck Research Laboratories, are scheduled to participate at the Morgan Stanley Global Healthcare Conference in New York on Sept. 9, 2014 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to live audio presentation of the webcasts at http://www.merck.com/investors/events-and-pre.../home.html.
Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:30PM CDT
Bristol-Myers (BMY) filed a patent infringement case against Merck (MRK).
U.S. Northeast Remains Life-Science Darling, Attracting $8 Billion in Capital Investment, an Industrial Info News Alert
Marketwire - 11 mins ago
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Like any long-term union, the one shared between the U.S. Northeast region, which comprises Delaware, New Jersey, New York and Pennsylvania, and the Life Science Industry is a classic example of a love/hate relationship. The Northeast region has been pummeled over the past few years with scores of pharmaceutical plants closing and lucrative jobs lost. On the other hand, the region remains a favorite for capital investment from both the private and public sectors for new and upgraded life-science manufacturing plants and research centers. Currently, there are 147 active reported projects translating to a hefty $7.8 billion in total investment value.
Global Migraine Drug Forecast and Market Analysis to 2023 - A Potential $3.7 Billion Market
M2 - 1 hr 34 mins ago
Research and Markets (http://www.researchandmarkets.com/research/5qmmg2/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023" report to their offering. The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile. Key Findings - The main driver of the expansion of the migraine market will be the continuous use of Botox for chronic migraine. The introduction of reformulations of mature products as well as new classes of therapies will further increase the market size. - The biggest barrier for the introduction of new therapies will be patent expirations of the majority of the drugs marketed for migraine, which have resulted in an increase of generics, and which may negatively impact revenue from branded drugs that are expected to launch in the forecast period. - The concerns of reducing healthcare costs as part of government austerity measures, particularly in Europe, which will impede market growth. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - GlaxoSmithKline - AstraZeneca - Merck - Vernalis - Almirall - Pfizer - Zogenix - NuPathe - Allergan - RedHill Biopharma - OptiNose - CoLucid Pharmaceuticals - SUDA - Revance Therapeutics - NeurAxon For more information visit http://www.researchandmarkets.com/research/5q...harmapoint
Ligand Inks 2nd Captisol Deal with CURx Pharmaceuticals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 4:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) entered into a licensing deal with CURx Pharmaceuticals, under which the former's Captisol-enabled lamotrigine program will be developed and commercialized.
Pipeline Analysis of Hospital Acquired Pneumonia Drugs 2014-2020: Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix
M2 - Wed Sep 10, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r49n8b/pipeline_analysis) has announced the addition of the "Pipeline Analysis of Hospital Acquired Pneumonia Drugs - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of hospital acquired pneumonia are common in immunocompromised patients, post surgical infections, enteral feeding, elderly and infant patients. As hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator associated pneumonia. Major causative pathogens include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne. Currently there are four drugs authorized for treatment of hospital acquired pneumonia; these include Zosyn (piperacillin/tazobactam), Zyvox (linezolid), Tygacil (tigecycline), and Vibativ (telavancin). Consistent research and development is being conducted in view of introducing more effective treatment options. There are five investigational drugs and one vaccine in stage III clinical trials, while ten other candidates in early stage, which mainly include biological drugs. Tedizolid phosphate and ceftolozane/tazobactam by Cubist Pharmaceutical, ceftazidime/avibactam by AstraZeneca PLC, amikacin inhale by Bayer Healthcare, plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline are the phase III candidates. Considering the antibacterial efficiency, and current market competition, tedizolid phosphate is expected to be the most preferred drug for treatment of nosocomial pneumonia. Amikacin inhale, an aerosolized drug is intended for sale as a drug device combination. Majority of the drugs in the late stages are biological drugs. Aridis Pharmaceutical holds four investigational drugs against various causative agents of hospital acquired pneumonia, each being monoclonal antibody therapy. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market overview Chapter 4 Hospital Acquired Pneumonia, Pipeline Analysis Chapter 5 Global Pipeline Review of Hospital Acquired Pneumonia Drugs Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Valneva SE - Achaogen, Inc. - Aridis Pharmaceuticals - AstraZeneca plc - Cubist Pharmaceuticals, Inc. - GlaxoSmithKline, Inc. - Meiji Seika Pharma Co. Ltd. - Merck & Co. Inc. - Sanofi For more information visit http://www.researchandmarkets.com/research/r4...e_analysis
Dow Component Merck (MRK) To Go Ex-dividend Tomorrow
at The Street - Wed Sep 10, 10:00AM CDT
Thursday, September 11, 2014 is the ex-dividend date for Dow component (NYSE:MRK).
Global Diclofenac Market Report 2014-2019
M2 - Wed Sep 10, 9:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tmxmbx/global_diclofenac) has announced the addition of the "Global Diclofenac Industry Report 2014" report to their offering. The report provides an basic overview of the industry including definitions, classifications, applications and industry chain structure. The diclofenac market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Diclofenac industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on twenty-six industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The diclofenac industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Diclofenac Industry Overview - Global Diclofenac Market Status Analysis - Major Regions Diclofenac Market Status Analysis - Major Countries Diclofenac Market Status and Analysis - Major Companies Diclofenac Market Status and Analysis - Diclofenac Industry Chain and Marketing Channels Analysis - Diclofenac Industry Development Trend - Diclofenac New Project Investment Feasibility Analysis - Global Diclofenac Industry Research Conclusions Companies Mentioned - A. S. Joshi And Company - Asa Biotech - Ausun - Anyang Jiuzhou Pharmaceutical Co., Ltd. - Bayer - Cpu-Pharma - Dezhou Deyao Pharmaceutical Co.,Ltd - Hainan Poly Pharm - Istituto Biochimico Italiano Spa - Iroko - Kahan Pharmaceuticals - Merck Sharp & Dohme Corp. - Metrix Healthcare Private Limited - Novartis - Nipa Pharmaceuticals Limited - Pku Healthcare Corp.,Ltd - Pfizer - Raazee Therapeutics (Pvt) Ltd. - Simcere - Sunij - Suzhou Homesun Pharmaceutical Co.,Ltd - Sri Pharmacare - Warrant Pharmaceutical - Yung Zip Chemical Co. Limited - Yangtze River Pharmaceutical Group - Zhejiang Jinhua Conba Bio-Pharm Co.Ltd For more information visit http://www.researchandmarkets.com/research/tm...diclofenac About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Merck & Co.'s Keytruda is Approved in the United States for the Treatment of Advanced and Unresectable Malignant Melanoma
PR Newswire - Wed Sep 10, 9:00AM CDT
The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma. Decision Resources Group will track the launch of Keytruda throughout its first year on the market through our syndicated LaunchTrends report series.
OTC Drug Market in India 2014
M2 - Wed Sep 10, 3:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2nxxm7/otc_drug_market) has announced the addition of the "OTC Drug Market in India 2014 " report to their offering. This latest market research report titled OTC Drug Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing self-medicated patient population, growing confidence in OTC drugs, and change of prescription drugs to OTC drugs are the key drivers of this market. The various segments of OTC drugs such as Vitamins & Minerals, Gastrointestinal, and Cough Cold & Allergy etc. are the major reasons for the popularity of the OTC drug market. Growing number of self-treatment patient base and their confidence in the OTC drugs is helping the Indian market to grow. Prescription drugs, after becoming OTC, present a huge opportunity for growth. OTC drugs increase the availability of different types of drugs intended for self-medication among patients, which helps in the growth of the market. The increasing disposable income of people is also helping to boost the market size. Some challenges faced by the industry are the internal competition between large pharmaceutical companies. Another challenge is the penetration of OTC drugs in rural areas which is very low. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well. Key Topics Covered: - Executive Summary - Macroeconomic Indicators - Introduction - Market Overview - Value Chain - Drivers & Challenges - Government Initiatives - Regulations - Competitive Landscape - Recent Developments - Strategic Recommendation - Appendix Companies Mentioned Public Companies - Amrutanjan Healthcare Ltd. - Cipla Ltd. - Dr. Reddy's Laboratories Ltd. - GlaxoSmithKline Pharmaceuticals Ltd. - Lupin Ltd. - Novartis India Ltd. - Pfizer Ltd. - P&G - Ranbaxy Laboratories Ltd. - Merck Ltd Sun Pharmaceutical Industries Ltd.. For more information visit http://www.researchandmarkets.com/research/2n...rug_market
Broccolini and Magil Laurentian Announce the Acquisition of the Former Merck Canada Complex in Kirkland, Quebec
PR Newswire Europe - Tue Sep 09, 5:10PM CDT
KIRKLAND, Quebec, September 9, 2014 /PRNewswire/ --
TESARO Seeks FDA Approval for NK-1 Receptor Rolapitant - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:00PM CDT
TESARO, Inc. (TSRO) submitted a new drug application for its pipeline candidate, oral rolapitant, to the FDA.
Broccolini and Magil Laurentian announce the acquisition of the former Merck Canada complex in Kirkland, Quebec
PR Newswire - Tue Sep 09, 2:08PM CDT
Broccolini Limited Partnership No. 2 and Magil Laurentian Realty Investments announced today that they have closed on the acquisition of the former Merck Canada complex along the TransCanada Highway in Kirkland, Quebec. Broccolini and Magil Laurentian have joined forces to develop this world-class 50-acre business and mixed-use campus which was renamed "Quartier Évolution". The partnership between Broccolini and Magil Laurentian brings together a qualified team of professionals in construction, real estate development and property management, in order to fully meet the needs of future tenants.
Watch for Shares of Merck (MRK) to Approach Support at $60.57
Comtex SmarTrend(R) - Tue Sep 09, 12:26PM CDT
Merck (NYSE:MRK) has opened bearishly below the pivot of $61.07 today and has reached the first level of support at $60.81. Analysts will be watching for a cross of the next downside pivot targets of $60.57 and $60.07.
Cardiovascular Pharmaceuticals Market in India 2014
M2 - Tue Sep 09, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rgkkvk/cardiovascular) has announced the addition of the "Cardiovascular Pharmaceuticals Market in India 2014" report to their offering. This market research report titled Cardiovascular Pharmaceutical Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing patient population, patent expiry of blockbuster drugs, and introduction of newer and better drugs are the key drivers of this market. Cardiovascular pharmaceuticals is one of the leading therapeutic segments of the overall pharma industry and cardiovascular diseases (CVDs) are the top causes of deaths worldwide Growing incidences of cardiovascular diseases is helping the Indian market to grow and large pharmaceutical companies are trying to launch new patented blockbuster drugs to tackle the situation. Patented blockbuster drugs, after becoming generic, present a huge opportunity for growth. Generic drugs increase the affordability among patients, which helps in the growth of the market. The increasing disposable income of people are also helping to boost the market size. Some challenges faced by the industry are the internal competition between large pharmaceutical companies and competition from complementary and alternative medicines. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well Key Topics Covered: - Executive Summary - Macroeconomic Indicators - Introduction - Market Overview - Value Chain - Drivers & Challenges - Government Initiatives - Competitive Landscape - Recent Developments - Strategic Recommendation - Appendix Companies Mentioned Public Companies: - AstraZeneca Pharma India Ltd. - Sanofi India Ltd. - Cipla Ltd. - Dr. Reddy's Laboratories Ltd. - GlaxoSmithKline Pharmaceuticals Ltd. - Lupin Ltd. - Merck Ltd. - Novartis India Ltd. - Pfizer Ltd. - Ranbaxy Laboratories Ltd. - Sun Pharmaceutical Industries Ltd. - Torrent Pharmaceutical Ltd. Private Companies: - Bristol-Myers Squibb India Pvt. Ltd. - Cadila Pharmaceuticals Ltd. - Intas Pharmaceuticals Ltd. - USV Ltd. For more information visit http://www.researchandmarkets.com/research/rg...iovascular
Four New Partner Organizations Join Optum Labs Research Collaborative
Business Wire - Tue Sep 09, 7:01AM CDT
Optum Labs, the collaborative research and innovation center co-founded by Optum and Mayo Clinic, announced the addition of four new partners committed to improving the quality and value of patient care.
Merck kicks off its second year fight against diabetes by adopting e-learning solutions to build healthcare capacity in Africa
M2 - Tue Sep 09, 6:52AM CDT
- Merck is reaching to health professionals in rural areas by providing SMS and e-learning platform for diabetes
Global Infectious Disease Treatment Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, GSK, J&J Merck & Pfizer
M2 - Tue Sep 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5tdjb4/global_infectious) has announced the addition of the "Global Infectious Disease Treatment Market 2014-2018" report to their offering. The analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 3.43% over the period 2013-2018. Infectious diseases can be caused by various pathogenic microorganisms such as bacteria, fungi, parasites, or viruses. These diseases can be transmitted from one individual to another through either direct contact or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on the target organism, anti-infective drugs can be categorized into antibacterial, antiviral, antifungal, and antiparasitic. One of the emerging trends in this market is the emergence of Interferon-free regimens. Various all-oral, IFN-free regimens are under development and are expected to attain higher sustained virologic response and cause fewer side effects than the currently approved therapies. According to the report, the launch of Direct-acting Antivirals is one of the major drivers for the Global Infectious Disease Treatment market. DAAs are administered in combination with other antiviral drugs such as ribavirin and PEG-IFN and increase the efficacy of treatment and decrease the duration of therapy and this leads to increased preference for this treatment among patients. Further, the report states that a generic erosion of marketed drugs is one of the major challenges faced by the market. A loss of patent protection and market exclusivity generally triggers the entry of low-cost alternatives for drugs, which, in turn, decreases the sales of innovator-approved drugs. To calculate the market size, the report considers the revenue generated through the sales of various drugs administered to treat various infectious diseases caused by bacteria, virus, fungi, and parasites, which include: - Antibacterial drugs (beta-lactams, macrolides, aminoglycosides, phenicols, quinolones, sulfonamides, tetracyclines, and other antibacterials) - Antiviral drugs (HIV, hepatitis C, hepatitis B, and other antivirals) - Antifungal drugs (azoles, pyrimidines, echinodians, polyenes, allylamines, and other antifungal drugs) - Antiparasitic drugs Key Vendors - F. Hoffmann-La Roche - Gilead Sciences - GlaxoSmithKline - Johnson & Johnson - Merck - Pfizer For more information visit http://www.researchandmarkets.com/research/5t...infectious
Acucela Appoints Biotechnology Industry Veteran and Former Pharmaceutical Executive, Brian O'Callaghan, as Its New President and Chief Operating Officer and Interim CFO; Ryo Kubota, MD, PhD, to Remain in His Role as Chairman and CEO
Business Wire - Mon Sep 08, 7:15PM CDT
Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that after a long and thoughtful strategic planning process to recruit a new President and Chief Operating Officer (COO), Acucela has appointed Brian O'Callaghan, who currently sits on Acucela's Board of Directors, to the newly created position, effective immediately. Ryo Kubota, MD, PhD, who is also Acucela's Founder, will remain as Acucela's Chairman of the Board (Chairman) and Chief Executive Officer (CEO). In a separate development, Acucela's Chief Financial Officer (CFO), David Lowrance, will be leaving the Company for family reasons. As a result of Mr. Lowrance's departure, Mr. O'Callaghan will also assume the role of Interim CFO. An active search is underway to appoint a new CFO. Mr. O'Callaghan brings to Acucela over 25 years of leadership experience in the biotechnology and pharmaceutical industries, including senior positions at Bayer, Merck, Novartis, NPS Pharmaceuticals, Pfizer, and Sangart. He will report directly into Dr. Kubota.
Merck to Participate at the Morgan Stanley Global Healthcare Conference
Business Wire - Mon Sep 08, 4:00PM CDT
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer; Adam H. Schechter, executive vice president and president, Global Human Health; and Dr. Roy Baynes, senior vice president, Clinical Development, Merck Research Laboratories, are scheduled to participate at the Morgan Stanley Global Healthcare Conference in New York on Sept. 9, 2014 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to live audio presentation of the webcasts at http://www.merck.com/investors/events-and-pre.../home.html.
Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:30PM CDT
Bristol-Myers (BMY) filed a patent infringement case against Merck (MRK).
